Mika Reiner Mayer is widely recognized as one of the leading intellectual property and patent strategy attorneys in the life sciences industry, with extensive expertise spanning patent prosecution, strategic portfolio management, IP diligence, post grant proceedings, and high value transactional support involving biotechnology, pharmaceuticals, medical devices, diagnostics, drug delivery systems, and advanced healthcare technologies. Based in Silicon Valley, she is regarded as one of the premier strategic IP advisors for both emerging growth life sciences companies and the venture capital and private equity firms that invest in them.

Mika is a Partner at Cooley LLP, one of the world’s leading law firms serving the life sciences, healthcare, technology, venture capital, and emerging company sectors. Cooley is internationally recognized for its dominant position representing venture backed companies, biotechnology innovators, medical technology enterprises, and transformational growth businesses, with one of the largest and most respected life sciences patent practices in the world. Mika joined Cooley after previously serving in leadership roles at Morrison & Foerster, where she co-founded and led the firm’s venture intellectual property group and also led its medical device patent practice.

Throughout her distinguished career, Mika has led hundreds of patent diligence and portfolio strategy matters ranging from early stage seed financings to multibillion dollar mergers, acquisitions, and strategic transactions. Her work spans both company side and investor side representation involving some of the most prominent organizations within biotechnology, healthcare, medical technology, and venture capital. Representative company clients have included Gilead Sciences, Allogene Therapeutics, W.L. Gore & Associates, Myovant Sciences, Intersect ENT, Intuity Medical, Sight Sciences, Freedom Innovations, and Gauss Surgical. On the investor side, she has represented leading venture and strategic investment firms including Kleiner Perkins, GE Ventures, Canaan Partners, Vertex Healthcare Ventures, and Vivo Ventures.

Mika is particularly recognized for her ability to translate highly complex intellectual property risks into clear strategic business guidance for executive teams, boards of directors, investors, and acquirers. Her strategic counsel has helped numerous life sciences and medical technology companies successfully scale, complete financings, execute strategic partnerships, go public, or achieve successful acquisitions. Her work spans sophisticated patent prosecution strategy, portfolio management, freedom to operate analysis, diligence review, licensing, commercialization strategy, and transaction support involving some of the most technically advanced and competitive sectors within healthcare and biotechnology.

She has also developed extensive expertise in post grant review proceedings, patent disputes, and litigation related matters, where she works closely with litigation teams, patent owners, petitioners, plaintiffs, and defendants to develop efficient, commercially focused, and strategically aligned intellectual property solutions. Her combined technical, legal, and business expertise has made her one of the most highly regarded strategic IP advisors in the life sciences industry.

Mika has received extensive national and international recognition for her work in intellectual property law and patent strategy. She has consistently been ranked in the highest tier by Chambers USA for intellectual property and patent prosecution in California and has been recognized by numerous leading legal and industry publications including IAM Patent 1000, Managing Intellectual Property, Legal 500, LMG Life Sciences, The National Law Journal, Law360, The Recorder, The American Lawyer, Daily Journal, and Super Lawyers.